John P. Walker

Interim Chief Executive Officer

John P. Walker has served as a member of our board of directors since May 2016. Mr. Walker currently serves as Executive Chairman and Interim Chief Executive Officer of Vizuri Health Sciences, LLC and was most recently a Managing Director of Four Oaks Partners, a life sciences transaction advisory firm. His past positions included Chairman and Chief Executive Officer roles at Novacea, Kai Pharmaceuticals, Renovis, Axys Pharmaceuticals, Microcide, Signal Pharmaceuticals and other life sciences companies. Mr. Walker is a graduate of the Advanced Executive Program at The Kellogg School of Management at Northwestern University and holds a B.A. from the State University of New York at Buffalo.

Georgia Erbez

Chief Business Officer, CFO

Georgia Erbez, our Chief Business Officer and Chief Financial Officer,  joined Zosano in September 2016. Ms. Erbez previously consulted to Zosano as Interim CFO from June 2016 to September 2016. Prior to Zosano, Ms. Erbez provided strategic consulting and interim financial management services to several public and private biotechnology companies. Previously, she served as CFO, Secretary, and Treasurer to Raptor Pharmaceuticals from 2012 to 2014. She was a key member of the management team that guided Raptor through a growth phase including first drug approval and commercial drug launch.  Prior to Raptor, Ms. Erbez spent over 20 years as an investment banker focused on advising and raising capital for emerging growth life sciences companies. She was a founder of Beal Advisors and held senior positions at Collins Stewart, Jeffries & Company, Inc. and Cowen and Company. She has also held positions of increasing responsibility at Hambrecht & Quist and Alex, Brown & Sons Inc. Ms. Erbez was awarded a Bachelor of Arts degree, International Relations from the University of California at Davis.

Donald Kellerman, PharmD

VP, Clinical Development and Medical Affairs

Dr. Kellerman has served as our Vice President of Clinical Operations since July 2015. Prior to joining Zosano, Dr. Kellerman served as Senior Vice President of Clinical Development & Regulatory Affairs at Tonix Pharmaceuticals. Previously, Dr. Kellerman served as Senior Vice President of Clinical Development & Medical Affairs at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) for five years. Dr. Kellerman also held the position of Senior Vice President of Development at Inspire Pharmaceuticals, Inc. for nine years, where he was responsible for all aspects of drug development, including clinical research, regulatory affairs, project management and biostatistics. He also led groups responsible for running several clinical programs in the respiratory, ophthalmology and cardiovascular areas. In addition, Dr. Kellerman has served in various clinical and project leadership positions at Glaxo Wellcome, Sepracor, Inc., and E.R. Squibb and Sons, Inc. He has more than 25 years of experience in the development of prescription pharmaceuticals and has lead- or co-authored more than 80 publications. Dr. Kellerman holds Doctor of Pharmacy and Bachelor of Science degrees from the College of Pharmacy at the University of Minnesota.

Hayley Lewis, RAC

VP, Regulatory Affairs & Quality

Hayley Lewis has served as our Vice President of Regulatory Affairs and Quality since October 2015. Prior to joining Zosano, she was Vice President of Regulatory Affairs and Quality at Carbylan Therapeutics. While at Carbylan, Ms. Lewis was part of the executive team that took the company public in April of 2015, as well as being responsible for all regulatory and quality activities, both internally and for external development programs for the company. From 2003 to 2014, Ms. Lewis held positions of increasing responsibility, most recently the Senior Director of Regulatory Affairs at Depomed, Inc. During her tenure, she led the company in the approvals of three NDAs, Proquin®, Glumetza®, and Gralise®, as well as approvals of several supplemental NDAs for Gralise®, Cambia®, Zipsor® and Lazanda®, including a line extension for Glumetza®, CMC, and labeling changes for the neurology and pain product lines for Depomed’s portfolio. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich, and completed the Executive Program for Women Leaders at the Stanford Graduate School of Business.

Eric Scharin

VP, Operations & Engineering

Eric Scharin has served as our Vice President of Operations & Engineering since April, 2015. He has played a key role in the approval of five commercial pharmaceutical products, most recently Sumavel® DosePro® and Zohydro® ER in his role as Sr. Director of Engineering and Product Industrialization at Zogenix from 2007 to 2015. Prior to Zogenix, Mr. Scharin served as Director of Manufacturing at Tercica from 2003 to 2007, where he led the CM&C team which developed the successful MAA for Increlex (IGF-1). Mr. Scharin has also served in manufacturing, validation, process development, and engineering roles at Sensus Drug Development, Covance Biotechnology Services, and Biogen. Mr. Scharin received an M.S.C.E.P. degree from the Massachusetts Institute of Technology and a B.S. in Chemical Engineering from the California Institute of Technology.